Ozempic and Autoimmune Disease: Not What You Think

These drugs genuinely calm inflammation, and the newest data also hint they might slightly raise your odds of a new autoimmune condition. Same drugs, two opposite effects, and here is the honest, unresolved answer.

Can Ozempic or Zepbound actually help your autoimmune disease? If you have been looking for the real answer instead of the version making the rounds online, this one is for you.

I am a quadruple board-certified allergy, immunology, and lifestyle medicine physician, and I live with Sjögren's disease and dysautonomia myself. So when a patient asks me whether one of these medications could help their condition, I am thinking about it not only as a doctor, but as someone who navigates this personally. I want to walk you through what GLP-1 medications actually do to your immune system, what we know and what we do not know for autoimmune disease and for Sjögren's specifically, and the cautions that matter most if you are considering one.

A quick but important note before we start: this is education, not medical advice, and it is not me telling you to start or stop any medication. That conversation is between you and your care team.

Same drugs, different labels

Ozempic and Wegovy are the same medication, called semaglutide. Mounjaro and Zepbound are the same medication, called tirzepatide. In each pair, the first name is approved for diabetes and the second for weight loss. Same drugs, different labels.

The part that is real: these drugs are genuinely anti-inflammatory

These medications do more than lower blood sugar and turn down appetite, and there is nuance that even a lot of doctors get wrong. They are not mainly working by plugging straight into your immune cells. Immune cells barely carry the receptor for GLP-1 at all. Most of the anti-inflammatory effect appears to be indirect, running through the lining of your gut and through a signal up to your brain that then tells the rest of the body to turn inflammation down (Wong & Drucker 2025; Wong et al. 2024; Wong et al. 2022; Lee & Jun 2016).

However it gets there, the effect itself is real. These drugs quiet some of the body's key inflammatory switches, including a signaling pathway called NF-kappaB and the NLRP3 inflammasome, an alarm system inside your cells that, when it is stuck on, can drive chronic inflammation. In a large meta-analysis of randomized trials, GLP-1 drugs lowered CRP, the background-noise inflammation marker in the body, on top of their effects on blood sugar and other markers (Kanbay et al. 2026).

The honest truth: no Sjögren's trials exist

Here is where the internet gets way ahead of the evidence. When it comes to Sjögren's disease and many autoimmune diseases specifically, we do not have a single clinical trial of these drugs, not one (Deng et al. 2025; Bilgin et al. 2025). Sjögren's shows up on the list of conditions researchers think are theoretically interesting, but there is no evidence right now that GLP-1 medications improve dry mouth, salivary gland function, or Sjögren's disease activity in any way.

The autoimmune evidence that does exist is early, and it lives mostly in other conditions. The strongest signals so far are in psoriasis and psoriatic arthritis, with a fairly large body of observational data in inflammatory bowel disease showing people on these drugs needed less steroid use and had fewer hospitalizations, plus early laboratory-level work in rheumatoid arthritis (Birda et al. 2025; Bilgin et al. 2025). Add up all of the rheumatic diseases and you get roughly 52 studies and 7 clinical trials, most with real limitations, and none of that work has been head-to-head against the medications we already use to treat those diseases.

The safety paradox: two studies, two signals

This is the paradox I flagged at the start, and I want to give you both halves, because the honest picture is genuinely mixed.

In one large study of over 229,000 people, being on a GLP-1 did not raise, and did not lower, the risk of developing a new autoimmune disease (Karacabeyli et al. 2026). That part is reassuring.

But in a second large comparison, with around 290,000 people in each group, researchers found the opposite signal: a modest increase in several autoimmune conditions, including autoimmune thyroid disease, psoriasis, ulcerative colitis, and rheumatoid arthritis (Lee YJ et al. 2025).

So we are sitting with a real, honest, unresolved paradox. These drugs seem to calm inflammation on one hand and yet may slightly nudge up the odds of certain autoimmune conditions on the other, and no one has fully explained why yet. What that means for you is not to panic. It means being thoughtful and having a little caution, and watching this space closely with a clinician who knows your history and can think it through with you critically. As of today, this is not an approved treatment for autoimmune disease.

The hopeful side of the research

A few years ago, we were not even asking this question. Today we have an entire class of medications that can quietly calm inflammation through a completely new pathway, and autoimmune research is growing every month. Some of the smartest people in immunology are genuinely excited about where this could go, and that is real reason for optimism. The moment we have actual evidence in autoimmune disease, especially in Sjögren's and dysautonomia, I will bring it straight to you.

The benefit that actually matters: your heart

Is there a benefit that matters for our community? Yes, and it is probably not the one you would guess. It is your heart.

Cardiovascular disease is the leading cause of early death in people with autoimmune rheumatic diseases, and that is not said to scare you. It is said because it is the part that too often gets ignored while everyone focuses on the joints, the fatigue, and the dryness. Here is where the data are actually strong: in people who have an immune-mediated inflammatory disease plus type 2 diabetes, starting one of these medications was linked to lower overall mortality and fewer major cardiac events like heart attack and stroke, and those benefits appeared to hold even independent of how much weight or blood sugar changed (Karacabeyli et al. 2024). If you carry extra cardiovascular risk, and many of us with autoimmune diseases do because it is part of the disease itself, that is a conversation worth having with your doctor.

The cautions that matter for you

Save this section for your next appointment, especially if you have Sjögren's disease or dysautonomia.

Caution one: your gut

A big part of how these drugs work is by slowing how fast your stomach empties. For a lot of people, that is fine. But if you already have a slow, sluggish gut, which can come along with dysautonomia and is common in Sjögren's, slowing it down further can cause real problems. Severe gastroparesis, a stomach that empties far too slowly, is considered a reason not to use these drugs at all (Jalleh et al. 2026; Rosen & Ingelfinger 2026). If you have any history of a slow stomach, nausea, early fullness, or bloating, that needs a thoughtful conversation before you start.

Caution two: dryness and dehydration

Dehydration is the most common serious metabolic side effect of these medications, usually from the nausea, vomiting, or diarrhea they can cause (He et al. 2024). If you already live with dryness symptoms and may be starting from a fluid deficit, that could be a bigger problem. There are also safety signals for dry mouth specifically. In fairness, one very large study of over 226,000 people did not find an overall increase in most mouth and salivary problems (Mawardi 2023; Oyewole et al. 2026). So this is a monitor-closely-and-hydrate situation, not a never, but you have to go in with a hydration plan.

Caution three: muscle and bone

When people lose weight on these drugs, a meaningful part of that loss, around a quarter to a third in some analyses, may be muscle, not just fat, and there are early signs of some bone density loss as well (Batsis et al. 2026; Jalleh et al. 2026). If you are already deconditioned or dealing with fatigue, losing muscle and possibly bone is the last thing you want. If you go this route, protein and resistance training are not optional. They have to be part of the plan.

So who might this actually help?

Let me be clear about who this may generally make sense for. This is not a cure for autoimmune disease, and I would be skeptical of anyone selling it that way.

But if you have Sjögren's alongside something like obesity, metabolic syndrome, type 2 diabetes, elevated cardiovascular risk, or sleep apnea, there is a real, evidence-based rationale, mostly through metabolic benefit, heart protection, and lower inflammation, that is worth the conversation (Bilgin et al. 2025; Kyriazi et al. 2025; Mozaffarian et al. 2025; Rosen & Ingelfinger 2026). That is a different reason to consider one of these medications than hoping it fixes your dry eyes or dry mouth. It can be a reasonable tool for the right person, decided with a clinician who is looking at your whole picture, not a wellness influencer who has never seen your chart.

How to have a smart conversation with your doctor

If, after all of this, you are still curious about a GLP-1, here is how to have that conversation well:

• If you have dysautonomia or any slow-stomach symptoms, ask your doctor to look at your gut motility before you start.
• Make a hydration and dry-mouth plan up front, especially if your dryness is already significant.
• Protect your muscle from day one with a protein target and some form of resistance training.
• Know the hard stops. If you or a close family member has had specific types of thyroid cancer or certain other conditions, these drugs may not be right for you (Jalleh et al. 2026; Rosen & Ingelfinger 2026).
• Set your expectations honestly. If you and your doctor decide this is a good fit, for metabolic or heart reasons, know that we do not have data to say it is treating your Sjögren's disease, at least not yet.

Where this leaves you

If you have wondered whether one of these medications could help your autoimmune disease, that is a genuinely smart question, not a vain one. The internet has made it almost impossible to get a straight and honest answer, which is exactly why I wanted to give you one.

You already know how to ask good questions of your own care. Now you have a clearer map for this specific one: what is proven, what is still open, and exactly what to bring to your next appointment.

Are you on, or have you considered, a GLP-1 medication? Tell me in the comments, because your experience helps the next person who finds this.

Keep going

• The RISE and Stronger Pathway: one short application, and our team, a physician, nurse practitioner, and health coach working from the same picture of you, helps you find the right fit, whether that is doctor-led medical care where our licenses allow, a guided coaching pathway, or the Stronger with Sjögren's community. If money is the barrier, still apply; there is a box on the form for our ACCESS fund, and checking it never counts against you. Start here: immuneconfidentinstitute.com/rise
• Free Lab Conversation Guide, for the appointment where you want your gut motility, hydration, and muscle questions on the table: immuneconfidentinstitute.com/ic-lab-guide
• IC Indicator Quiz, a free two-minute check-in on where your immune health stands right now: immuneconfidentinstitute.com/ic-indicator

Dr. Kara currently offers telehealth in 27 states: WI, AL, OH, MO, TX, KY, WA, GA, IL, PA, FL, WV, CO, MD, IN, UT, MI, TN, NV, NJ, MT, NC, LA, IA, ID, CT, AZ. Jen Henning, APRN, FNP-C, our nurse practitioner, is licensed in Florida and Ohio.

See more articles: